These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4215221)

  • 1. [Individual sensitivity of ovarian ascitic cancer to thiophosphamide].
    Karuzina NP; Shuvaeva NI; Klimanova ZF; Antoshechkina ET
    Vopr Onkol; 1974; 20(8):40-5. PubMed ID: 4215221
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of individual human tumour sensitivity to antitumour agents by tissue-slice incubation.
    Willoughby HW; Maughan GB; Tremblay PC; Wood N
    Can J Surg; 1971 Nov; 14(6):406-9. PubMed ID: 5170129
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy of ovarian cancer with melphalan.
    Rutledge F
    Clin Obstet Gynecol; 1968 Jun; 11(2):354-66. PubMed ID: 4971815
    [No Abstract]   [Full Text] [Related]  

  • 4. [A histochemical study of Shick-positive substances in cancerous tumors of the ovaries treated with thio-TEPA].
    Kasab'ian SS; Zaĭchenko IuM
    Akush Ginekol (Mosk); 1972 Jun; 48(6):71-3. PubMed ID: 4262647
    [No Abstract]   [Full Text] [Related]  

  • 5. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
    Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of the resistance of Guérin's carcinoma to thiophosphamide].
    Kaz'man SD
    Vopr Onkol; 1973; 19(7):65-71. PubMed ID: 4204162
    [No Abstract]   [Full Text] [Related]  

  • 8. [Possibilities of in-vitro culture of ascites and the testing of cytostatic agents].
    Schmidt F; Spitzbart H
    Dtsch Gesundheitsw; 1970 Jun; 25(23):1077-8. PubMed ID: 5524249
    [No Abstract]   [Full Text] [Related]  

  • 9. [Determination of individual sensitivity of malignant ovarian neoplasms to antineoplastic drugs].
    Kulik GI; Abragam KA
    Pediatr Akus Ginekol; 1969; 5():59-61. PubMed ID: 4994616
    [No Abstract]   [Full Text] [Related]  

  • 10. [Determination of the individual sensitivity of ovarian ascitic cancer cells in vitro by cytological criteria].
    Shuvaeva NI; Antoshechkina ET; Klimanova ZF
    Vopr Onkol; 1979; 25(7):101-4. PubMed ID: 113933
    [No Abstract]   [Full Text] [Related]  

  • 11. [Flow fluorescence-photometry in ovarian carcinomas with and without effusion].
    Krug H; Ebeling K
    Zentralbl Gynakol; 1976; 98(7):410-7. PubMed ID: 134608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of thiophosphamide in combination with thyroidectomy on the growth of Guérin's carcinoma and on the nucleic acid content in the tissues of tumor-bearing animals].
    Kirichenko LG
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1971; 12(96):31-4. PubMed ID: 5005624
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sensitivity of human tumor cells in culture to mitomycin C and thiophosphamide].
    Tolkacheva EN; Timofeevskaia EA
    Antibiotiki; 1973 Mar; 18(3):223-7. PubMed ID: 4202930
    [No Abstract]   [Full Text] [Related]  

  • 14. Metabolic activity of the Ehrlich ascites carcinoma cells and the significance of ascites serum addition.
    Miko M; Drobnica L
    Neoplasma; 1969; 16(2):161-9. PubMed ID: 5822918
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of thiophosphamide and 5-fluorouracil on the incorporation of H 3-thymidine into DNA of surviving ovarian cancer sections].
    Merkulov MF; Leskova SG
    Farmakol Toksikol; 1971; 34(2):220-8. PubMed ID: 4998193
    [No Abstract]   [Full Text] [Related]  

  • 16. High dose thiotepa in ovarian cancer.
    Shetty PA; Kurkure PA; Pai VR; Gohokar D; Pai S; Shinde SR; D'Souza LJ; Sampat MB
    Indian J Cancer; 1985 Mar; 22(1):33-7. PubMed ID: 3939232
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical studies of cancer patients treated with acridine derivative (C-283). IV. Changes in the levels of serum haptoglobin and sialic acid.
    Dobryszycka W; Osada J; Gerber J; Jablonski K
    Arch Immunol Ther Exp (Warsz); 1973; 21(2):271-9. PubMed ID: 4790848
    [No Abstract]   [Full Text] [Related]  

  • 18. [Chemo-hormonotherapeutic treatment of 20 cases of metastatic ovarian carcinoma].
    Gallo Curcio C; Casali A; Gianciotta A; Gionfra T; Rinaldi M; Terzoli L; Orofino G
    Clin Ter; 1979 Jul; 90(2):137-42. PubMed ID: 118841
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
    Decker DG; Malkasian GD; Mussey E; Johnson CE
    Am J Obstet Gynecol; 1967 Mar; 97(5):656-65. PubMed ID: 4959953
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute myeloblastic leukemia after cure of ovarian cancer.
    Greenspan EM; Tung BG
    JAMA; 1974 Oct; 230(3):418-20. PubMed ID: 4212912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.